DC Bead™ with doxorubicin
Superior pharmacokinetic profile

“It [DEBDOX®] achieves major tumor necrosis, while the side effects of chemotherapy are reduced due to its reduced passage into the systemic circulation... the peak concentration and the AUC were significantly lower than those of conventional TACE. The better profile of DEBTACE [DEBDOX®] vs conventional TACE opens the opportunity to increase the amount of drug selectively exposed to tumor cells and simultaneously, reduce toxicity.”

Varela M, Real MI, Burrel M et al.
J Hepatol 46 (2007): 474-481

Chemoembolization of Hepatocellular Carcinoma with Drug Eluting Beads: Efficacy and Doxorubicin Pharmacokinetics.
Varela M, Real MI, Burrel M et al. J Hepatol 46 (2007): 474-481

For more information on this article, scan here or visit: www.dcbeadbibliography.co.uk/Varela_Hepatology_2007

Important Safety Information

DC Bead® Indications:
• DC Bead® is CE marked and is indicated for the treatment of malignant hypervascular tumors and loading with doxorubicin drug
• DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC)

Both indications may not be available in your territory.
DC Bead® is not currently cleared by the FDA for sale or distribution in the USA. For instructions for use, please refer to: www.biocompatibles.com/dcbead-ifu

DC Bead® with Doxorubicin Cautions:
• Embolisation with DC Bead® should only be performed by a physician with appropriate interventional occlusion training in the region intended to be embolised
• Depending on the loading dose of 37.5 mg doxorubicin per 1 ml DC Bead® may lead to some systemic distribution of doxorubicin and related side effects

DC Bead® with Doxorubicin Potential Complications:
1. Unacceptable reflux or passage of DC Bead® into normal arteries adjacent to the targeted lesion or through the lesion into other arteries or arterial beds
2. Non-target embolisation
3. Pneumomediastinum
4. Ischaemia at an undesirable location
5. Pneumomediastinum and tissue damage
6. Ischemic stroke or ischaemic infarction
7. Nervous system deficits including cranial nerve palsies
8. Neurovascular deficits including spinal nerve palsies
9. Thrombosis
10. Death
11. Pneumothorax
12. Foreign body reactions necessitating medical intervention
13. Infection necessitating medical intervention
14. Clot formation at the tip of the catheter and subsequent dislodgement
DEBDOX®: Delivering the standard of care in intermediate HCC

Survival benefit confirmed with DC Bead™
For more information, scan here or visit: www.dcbeadbibliography.co.uk/Burrel_Hepatology_2012

Sustained drug release from DC Bead™ confirmed by histological explant data
For more information, scan here or visit: www.dcbeadbibliography.co.uk/Namur_Hepatology_2011

Improved efficacy vs conventional TACE, particularly in patients with advanced disease
For more information, scan here or visit: www.dcbeadbibliography.co.uk/Song_EJGH_2011

DEBDOX® technical recommendations
For more information, scan here or visit: www.dcbeadbibliography.co.uk/Lencioni_CVIR_2011

DEBDOX® with sorafenib is well tolerated, with excellent disease control
For more information, scan here or visit: www.dcbeadbibliography.co.uk/Pawlik_JCO_2011

PRECISION V: Improved tolerability & efficacy in more challenging HCC patients
For more information, scan here or visit: www.dcbeadbibliography.co.uk/Lammer_CVIR_2010

Improved outcomes over bland embolisation
For more information, scan here or visit: www.dcbeadbibliography.co.uk/Malagari_CVIR_2010

Superior pharmacokinetic profile
For more information, scan here or visit: www.dcbeadbibliography.co.uk/Varela_Hepatology_2007

Biocompatibles
Excellence in Interventional Oncology™

Product Name | DC Bead
---|---
Label Colour and Size | 100-300µm | 300-500µm | 500-700µm
Volume of Beads | 2ml | 2ml | 2ml
Product Code | DC2V103 | DC2V305 | DC2V607

For more information, please contact:
Biocompatibles UK Limited
Chapman House, Farnham Business Park, Weydon Lane, Farnham, Surrey, GU9 8QL, UK
Tel: +44 (0)1252 732 732
Fax: +44 (0)1252 732 777
email: marketing@biocompatibles.com
www.biocompatibles.com

DC Bead is manufactured by Biocompatibles UK Ltd, Chapman House, Farnham Business Park, Weydon Lane, Farnham, Surrey, GU9 8QL, UK. Biocompatibles UK Ltd is a BTG International group company. DEBDOX and Bead Block are registered trademarks and DC Bead is a trademark of Biocompatibles UK Ltd. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd. DC Bead is not currently cleared by the FDA for sale or distribution in the USA. © Copyright 2012 Biocompatibles UK Ltd. EC12-109 (TM) Rev 2.

The sizes of DC Bead™ used in the studies listed may not be the same as are shown in this image. Link to study details for more information.